Advertisement


Asaf Maoz, MD, on Pancreatic Cancer Screening: Potential Blood-Based Biomarkers

ASCO 2026

Advertisement

Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527). 



Related Videos

Breast Cancer

Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer

Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone receptor (HR)-positive, HER2-negative breast cancer, including genomic testing and systemic therapy.

Pancreatic Cancer

Jennifer J. Knox, MD, FRCPC, on RASolute 302 Findings: Expert Point of View

Jennifer J. Knox, MD, FRCPC, of Princess Margaret Cancer Centre, provides expert commentary on a phase III study of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic cancer (Abstract LBA5).

Gastroesophageal Cancer
Gastrointestinal Cancer

Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers

Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007). 

 

Lymphoma
Leukemia

Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL

Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstract 7012). 

Leukemia
Lymphoma

William G. Wierda, MD, PhD, on Pirtobrutinib in Treatment-Naive Patients With CLL/SLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, presents pooled results from the BRUIN CLL-313 and BRUIN CLL-314 trials. BRUIN CLL-313 is comparing pirtobrutinib to bendamustine plus rituximab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); BRUIN CLL-314 is comparing pirtobrutinib to ibrutinib in the same patient population (Abstract 7044). 

Advertisement

Advertisement




Advertisement